What is the most recent earnings date for CNSP stock?
CNS PHARMACEUTICALS INC (CNSP) last reported earnings on 11/14/2025.
NASDAQ:CNSP • US18978H5081
Past quarterly earnings results for CNS PHARMACEUTICALS INC (CNSP), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | -5.76 | -7.24 | 20.41% | 96.16% | - | - | ||
| Q2 2025 | -6.42 | -9.79 | 34.44% | - | - | - | ||
| Q1 2025 | - | - | - | - | ||||
| Q4 2024 | -111.00 | -118.24 | 6.12% | - | - | - | ||
| Q3 2024 | -150.00 | -61.20 | -145.10% | -13,788.89% | - | - | ||
| Q2 2024 | - | - | - | - | ||||
| Q1 2024 | - | - | - | - | ||||
| Q4 2023 | - | - | - | - | ||||
| Q3 2023 | -1.08 | - | 100.00% | - | - | |||
| Q2 2023 | - | - | - | - | ||||
| Q1 2023 | -2.59 | - | 100.00% | - | - | |||
| Q4 2022 | -2.45 | - | 100.00% | - | - | |||
| Q3 2022 | -81,000.00 | -73,440.00 | -10.29% | 35.71% | - | - | ||
| Q2 2022 | -81,000.00 | -73,440.00 | -10.29% | 40.00% | - | - | ||
| Q1 2022 | -63,000.00 | -100,980.00 | 37.61% | 53.33% | - | - | ||
| Q4 2021 | -90,000.00 | -146,880.00 | 38.73% | 44.44% | - | - | ||
| Q3 2021 | -126,000.00 | -149,175.00 | 15.54% | -16.67% | - | - | ||
| Q2 2021 | -135,000.00 | -119,340.00 | -13.12% | - | - | - | ||
| Q1 2021 | -135,000.00 | -110,160.00 | -22.55% | -25.00% | - | - | ||
| Q4 2020 | -162,000.00 | -107,865.00 | -50.19% | - | - | - | ||
| Q3 2020 | -108,000.00 | -114,750.00 | 5.88% | - | - | - | ||
| Q2 2020 | -135,000.00 | -73,440.00 | -83.82% | - | - | - | ||
| Q1 2020 | -108,000.00 | -91,800.00 | -17.65% | - | - | - |
Notes
CNS PHARMACEUTICALS INC (CNSP) last reported earnings on 11/14/2025.
CNS PHARMACEUTICALS INC (CNSP) beat EPS estimates and missed revenue estimates in the most recent quarter.